Tags : Pipeline

Biotech

Exelixis Signs an Exclusive License Agreement with WuXi Biologics to

Shots: WuXi Bio to receive up front and is eligible for development & commercialization milestones, along with royalties on sales of any potential products commercialized from the panel Exelixis get an exclusive license to the panel of mAb against an undisclosed oncology target for biologics applications Exelixis leverages WuXi Bio’s integrated technology platforms to develop […]Read More

Pharma

Intra-Cellular Reports the Expansion of Pipeline with the Addition of

Shots: Following the completion of a P-I program, the company plans to initiate P- II studies to evaluate ITI-1284 ODT-SL for the treatment of behavioral disturbances in dementia, dementia-related psychosis and certain depressive disorders in the elderly The P-I single and multiple ascending dose studies in healthy volunteers including elderly subjects aged >65yrs. evaluated the […]Read More

COVID-19 M&A

Sorrento to Acquire SmartPharm and Develop Pipeline of Gene-Encoded Therapeutic

Shots: Sorrento enters into letter of intent to acquire SmartPharm and develops pipeline of gene-encoded therapeutic Ab, initiating with Sorrento’s STI-1499 or COVI-GUARD, currently preclinical studies with an IND submission targeted for Aug’2020. The transaction is expected to be close in Aug’2020. The integration of Sorrento’s G-MAB Ab library and SmartPharm’s GET platform is expected […]Read More